DE10144903A1 - Vermehrung von Viren in Zellkultur - Google Patents

Vermehrung von Viren in Zellkultur

Info

Publication number
DE10144903A1
DE10144903A1 DE10144903A DE10144903A DE10144903A1 DE 10144903 A1 DE10144903 A1 DE 10144903A1 DE 10144903 A DE10144903 A DE 10144903A DE 10144903 A DE10144903 A DE 10144903A DE 10144903 A1 DE10144903 A1 DE 10144903A1
Authority
DE
Germany
Prior art keywords
virus
cells
medium
viruses
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE10144903A
Other languages
German (de)
English (en)
Inventor
Jens-Peter Gregersen
Juergen Vorlop
Christian Frech
Holger Luebben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Chiron Behring GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Behring GmbH and Co KG filed Critical Chiron Behring GmbH and Co KG
Priority to DE10144903A priority Critical patent/DE10144903A1/de
Priority to PT02777068T priority patent/PT1427817E/pt
Priority to NZ532203A priority patent/NZ532203A/en
Priority to CA002456561A priority patent/CA2456561A1/en
Priority to JP2003527090A priority patent/JP2005502357A/ja
Priority to BR0212469-6A priority patent/BR0212469A/pt
Priority to KR1020047003711A priority patent/KR100968141B1/ko
Priority to AT02777068T priority patent/ATE466932T1/de
Priority to DE50214416T priority patent/DE50214416D1/de
Priority to EP02777068A priority patent/EP1427817B1/de
Priority to US10/487,709 priority patent/US20050118698A1/en
Priority to SI200230909T priority patent/SI1427817T1/sl
Priority to HK04104986.4A priority patent/HK1062029B/xx
Priority to ES02777068T priority patent/ES2345606T3/es
Priority to PCT/EP2002/010207 priority patent/WO2003023025A1/de
Priority to DK02777068.4T priority patent/DK1427817T3/da
Priority to AU2002338666A priority patent/AU2002338666B2/en
Publication of DE10144903A1 publication Critical patent/DE10144903A1/de
Priority to JP2010145663A priority patent/JP2010246559A/ja
Priority to CY20101100718T priority patent/CY1110716T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12051—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE10144903A 2001-09-12 2001-09-12 Vermehrung von Viren in Zellkultur Ceased DE10144903A1 (de)

Priority Applications (19)

Application Number Priority Date Filing Date Title
DE10144903A DE10144903A1 (de) 2001-09-12 2001-09-12 Vermehrung von Viren in Zellkultur
EP02777068A EP1427817B1 (de) 2001-09-12 2002-09-11 Vermehrung von viren in zellkultur
US10/487,709 US20050118698A1 (en) 2001-09-12 2002-09-11 Multiplication of viruses in a cell culture
CA002456561A CA2456561A1 (en) 2001-09-12 2002-09-11 Multiplication of viruses in a cell culture
JP2003527090A JP2005502357A (ja) 2001-09-12 2002-09-11 細胞培養物中のウイルス増殖
BR0212469-6A BR0212469A (pt) 2001-09-12 2002-09-11 Método para multiplicação de vìrus em cultura de célula
KR1020047003711A KR100968141B1 (ko) 2001-09-12 2002-09-11 세포 배양물에서 바이러스의 증식 방법
AT02777068T ATE466932T1 (de) 2001-09-12 2002-09-11 Vermehrung von viren in zellkultur
DE50214416T DE50214416D1 (de) 2001-09-12 2002-09-11 Vermehrung von viren in zellkultur
PT02777068T PT1427817E (pt) 2001-09-12 2002-09-11 Multiplicação de vírus numa cultura celular
NZ532203A NZ532203A (en) 2001-09-12 2002-09-11 Cell culture system in which cell growth and virus multiplication occur concurrently
SI200230909T SI1427817T1 (sl) 2001-09-12 2002-09-11 Razmnoževanje virusov in celičnih kultur
HK04104986.4A HK1062029B (en) 2001-09-12 2002-09-11 Multiplication of viruses in a cell culture
ES02777068T ES2345606T3 (es) 2001-09-12 2002-09-11 Multiplicacion de virus en un cultivo celular.
PCT/EP2002/010207 WO2003023025A1 (de) 2001-09-12 2002-09-11 Vermehrung von viren in zellkultur
DK02777068.4T DK1427817T3 (da) 2001-09-12 2002-09-11 Formering af vira i cellekultur
AU2002338666A AU2002338666B2 (en) 2001-09-12 2002-09-11 Multiplication of viruses in a cell culture
JP2010145663A JP2010246559A (ja) 2001-09-12 2010-06-25 細胞培養物中のウイルス増殖
CY20101100718T CY1110716T1 (el) 2001-09-12 2010-07-30 Πολλαπλασιασμος ιων εντος κυτταροκαλλιεργειας

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10144903A DE10144903A1 (de) 2001-09-12 2001-09-12 Vermehrung von Viren in Zellkultur

Publications (1)

Publication Number Publication Date
DE10144903A1 true DE10144903A1 (de) 2003-03-27

Family

ID=7698761

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10144903A Ceased DE10144903A1 (de) 2001-09-12 2001-09-12 Vermehrung von Viren in Zellkultur
DE50214416T Expired - Lifetime DE50214416D1 (de) 2001-09-12 2002-09-11 Vermehrung von viren in zellkultur

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE50214416T Expired - Lifetime DE50214416D1 (de) 2001-09-12 2002-09-11 Vermehrung von viren in zellkultur

Country Status (16)

Country Link
US (1) US20050118698A1 (cg-RX-API-DMAC10.html)
EP (1) EP1427817B1 (cg-RX-API-DMAC10.html)
JP (2) JP2005502357A (cg-RX-API-DMAC10.html)
KR (1) KR100968141B1 (cg-RX-API-DMAC10.html)
AT (1) ATE466932T1 (cg-RX-API-DMAC10.html)
AU (1) AU2002338666B2 (cg-RX-API-DMAC10.html)
BR (1) BR0212469A (cg-RX-API-DMAC10.html)
CA (1) CA2456561A1 (cg-RX-API-DMAC10.html)
CY (1) CY1110716T1 (cg-RX-API-DMAC10.html)
DE (2) DE10144903A1 (cg-RX-API-DMAC10.html)
DK (1) DK1427817T3 (cg-RX-API-DMAC10.html)
ES (1) ES2345606T3 (cg-RX-API-DMAC10.html)
NZ (1) NZ532203A (cg-RX-API-DMAC10.html)
PT (1) PT1427817E (cg-RX-API-DMAC10.html)
SI (1) SI1427817T1 (cg-RX-API-DMAC10.html)
WO (1) WO2003023025A1 (cg-RX-API-DMAC10.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005245943A1 (en) * 2004-05-20 2005-12-01 Id Biomedical Corporation Process for the production of an influenza vaccine
RS51665B (sr) 2004-09-09 2011-10-31 Novartis Vaccines And Diagnostics Gmbh. Smanjenje potencijalnih jatrogenih rizika povezanih sa vakcinama protiv gripa
ATE494906T1 (de) 2005-11-01 2011-01-15 Novartis Vaccines & Diagnostic Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
WO2007052055A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
ES2377884T3 (es) 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
CA2628424A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted influenza vaccines including cytokine-inducing agents
KR20080069232A (ko) 2005-11-04 2008-07-25 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 스플리트 인플루엔자 백신에 대한 보조제로서 유리 수성상계면활성제를 갖는 에멀젼
WO2007110776A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
NZ575271A (en) * 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
AU2007347716B2 (en) 2006-09-15 2013-06-20 Medimmune, Llc MDCK cell lines supporting viral growth to high titers and bioreactor process using the same
PT2185191E (pt) 2007-06-27 2012-11-27 Novartis Ag Vacinas contra a gripe com baixo teor de aditivos
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CN102216450B (zh) 2008-09-24 2014-05-14 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法
KR20110074563A (ko) 2008-09-24 2011-06-30 메디뮨 엘엘씨 바이러스의 정제 방법
EP2361304A2 (en) 2008-11-05 2011-08-31 GlaxoSmithKline Biologicals S.A. Novel method
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
KR20120083480A (ko) * 2009-10-20 2012-07-25 노파르티스 아게 바이러스 구제를 위한 개선된 역유전학 방법
SG184833A1 (en) 2010-04-14 2012-11-29 Emd Millipore Corp Methods of producing high titer, high purity virus stocks and methods of use thereof
JP6072677B2 (ja) 2010-05-06 2017-02-01 ノバルティス アーゲー 微生物の不活化のための有機ペルオキシド化合物
JP5876036B2 (ja) 2010-05-21 2016-03-02 ノバルティス アーゲー インフルエンザウイルス再集合方法
PL2575872T3 (pl) 2010-06-01 2021-02-22 Seqirus UK Limited Zatężanie antygenów szczepionkowych grypy bez liofilizacji
CA2801151A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
CA2808965C (en) 2010-08-20 2020-01-07 Theraject, Inc. Soluble needle arrays for delivery of influenza vaccines
AU2012217170B2 (en) * 2011-02-17 2016-07-28 Boehringer Ingelheim Vetmedica Gmbh Commercial scale process for production of PRRSV
EP2686423A4 (en) 2011-03-14 2015-01-28 Nat Res Council Canada Method of viral production in cells
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
CN104159608A (zh) 2012-03-06 2014-11-19 克鲁塞尔荷兰公司 针对流感的改善的疫苗接种
US20150210986A1 (en) * 2012-08-24 2015-07-30 Ge Healthcare Bio-Sciences Corp. Virus purification and formulation process
KR101370512B1 (ko) 2013-06-07 2014-03-06 재단법인 목암생명공학연구소 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
AU2016290603B2 (en) 2015-07-07 2022-06-02 Seqirus UK Limited Influenza potency assays
CN105561317B (zh) * 2015-12-22 2018-03-20 肇庆大华农生物药品有限公司 重组伪狂犬病病毒疫苗耐热冻干保护剂及其制备方法
CN108239619A (zh) * 2016-12-23 2018-07-03 甘肃健顺生物科技有限公司 悬浮mdck细胞相关疫苗生产的二阶培养工艺技术
CN108570445A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 Pk15细胞驯化悬浮方法和二阶病毒生产工艺
CN108570444A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 St细胞驯化悬浮方法和二阶病毒生产工艺
CN108570454A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 Mdbk驯化悬浮方法和二阶病毒生产工艺
EP4061930A1 (en) 2019-11-18 2022-09-28 Seqirus Pty Ltd Method for producing reassortant influenza viruses
KR102444684B1 (ko) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법
CN115927755A (zh) * 2022-11-22 2023-04-07 辽宁成大生物股份有限公司 一种微量水痘-带状疱疹病毒的检测方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037000A1 (en) * 1996-04-01 1997-10-09 Chiron Behring Gmbh & Co. Animal cells and processes for the replication of influenza viruses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0878541A4 (en) * 1996-10-18 2001-10-17 Univ Osaka Res Found ROTAVIRUS ANTIGENS, VACCINALS AND MEDICATIONS AGAINST INFECTION BY ROTAVIRUS, AND METHOD FOR THEIR PRODUCTION
GB9915413D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Propagation method
CA2401117C (en) * 2000-03-03 2010-06-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037000A1 (en) * 1996-04-01 1997-10-09 Chiron Behring Gmbh & Co. Animal cells and processes for the replication of influenza viruses

Also Published As

Publication number Publication date
WO2003023025A1 (de) 2003-03-20
DE50214416D1 (de) 2010-06-17
JP2005502357A (ja) 2005-01-27
AU2002338666B2 (en) 2008-11-20
NZ532203A (en) 2005-04-29
EP1427817B1 (de) 2010-05-05
EP1427817A1 (de) 2004-06-16
CA2456561A1 (en) 2003-03-20
ES2345606T3 (es) 2010-09-28
ATE466932T1 (de) 2010-05-15
HK1062029A1 (zh) 2004-10-15
CY1110716T1 (el) 2015-06-10
KR100968141B1 (ko) 2010-07-06
PT1427817E (pt) 2010-08-10
DK1427817T3 (da) 2010-08-23
JP2010246559A (ja) 2010-11-04
SI1427817T1 (sl) 2010-08-31
US20050118698A1 (en) 2005-06-02
BR0212469A (pt) 2004-08-24
KR20050027164A (ko) 2005-03-17

Similar Documents

Publication Publication Date Title
DE10144906B4 (de) Verfahren zur großtechnischen Herstellung von Impfstoffen
EP1427817B1 (de) Vermehrung von viren in zellkultur
DE19612966B4 (de) MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE69732407T3 (de) Verfahren für die Replikation von Influenza in Zellkultur und die bei diesem Verfahren hergestellten Influenza-Viren
DE4407489A1 (de) Vakzine zur Prävention von Respirations- und Reproduktionserkrankungen des Schweines
DE69923470T2 (de) Kombinationsimpfstoff gegen hav und masernvirus und verfahren zu seiner produktion
CH504532A (de) Verfahren zur Züchtung pathogener Viren, Zellstamm zur Ausführung des Verfahrens und Anwendung des Verfahrens
EP0019218B1 (de) Influenzavirus-Vaccine, Verfahren zu ihrer Herstellung und Verfahren zur Vermehrung von Influenzaviren
EP2606128B1 (de) Permanente humane amniozyten zellinie zur herstellung von influenzaviren
DE19655440B4 (de) Verfahren zur Herstellung eines Influenzaimpfstoffs
El-Bagoury et al. Comparative potentiality study of three different vero cell culture systems for production of PPR Vaccine
HK1149046A (en) Method for manufacturing an active component of a medicine or diagnosis agent in mdcj cell suspension culture
DE2553827A1 (de) Wachstumsmedium fuer zellkulturen, verfahren zu seiner herstellung, zellkultivierungsverfahren und virusimpfstoff
HK1062029B (en) Multiplication of viruses in a cell culture

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8125 Change of the main classification

Ipc: A61K 35/76 AFI20051017BHDE

R081 Change of applicant/patentee

Owner name: NOVARTIS AG, CH

Free format text: FORMER OWNER: CHIRON BEHRING GMBH & CO., 35039 MARBURG, DE

Effective date: 20110615

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS GMBH, DE

Free format text: FORMER OWNER: CHIRON BEHRING GMBH & CO., 35039 MARBURG, DE

Effective date: 20110615

R082 Change of representative

Representative=s name: UEXKUELL & STOLBERG PARTNERSCHAFT VON PATENT- , DE

Effective date: 20110615

Representative=s name: UEXKUELL & STOLBERG, 22607 HAMBURG, DE

Representative=s name: UEXKUELL & STOLBERG, DE

Effective date: 20110615

R082 Change of representative

Representative=s name: UEXKUELL & STOLBERG, 22607 HAMBURG, DE

Representative=s name: UEXKUELL & STOLBERG, DE

R081 Change of applicant/patentee

Owner name: NOVARTIS AG, CH

Free format text: FORMER OWNER: NOVARTIS VACCINES AND DIAGNOSTICS GMBH, 35041 MARBURG, DE

Effective date: 20111209

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS GMBH, DE

Free format text: FORMER OWNER: NOVARTIS VACCINES AND DIAGNOSTICS GMBH, 35041 MARBURG, DE

Effective date: 20111209

R082 Change of representative

Representative=s name: UEXKUELL & STOLBERG PARTNERSCHAFT VON PATENT- , DE

Effective date: 20111209

Representative=s name: UEXKUELL & STOLBERG, 22607 HAMBURG, DE

Representative=s name: UEXKUELL & STOLBERG, DE

Effective date: 20111209

R016 Response to examination communication
R081 Change of applicant/patentee

Owner name: NOVARTIS AG, CH

Free format text: FORMER OWNER: NOVARTIS VACCINES AND DIAGNOSTICS GMBH, 35041 MARBURG, DE

R082 Change of representative

Representative=s name: UEXKUELL & STOLBERG, DE

Representative=s name: UEXKUELL & STOLBERG PARTNERSCHAFT VON PATENT- , DE

R002 Refusal decision in examination/registration proceedings
R003 Refusal decision now final